188 citations
,
October 2014 in “Thyroid” This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.
173 citations
,
July 2012 in “British Journal of Dermatology” This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.
6 citations
,
April 2013 in “Current Dermatology Reports” This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.
3 citations
,
June 2021 in “PLOS ONE” This study found that topical application of the BRAF inhibitor vemurafenib improved wound healing and promoted hair follicle regeneration in a diabetic murine model.